Abstract 30P
Background
Oral squamous cell carcinoma (OSCC) represents one of the six most common cancers in the world. The identification of new prognostic markers could help clinicians explore the biological characteristics of OSCC and develop more personalized treatment plans for patients based on their risk factors. The discovery and study of new prognostic markers of OSCC may help improve treatment outcomes through more accurate and effective treatment strategies, ultimately leading to improved survival and quality of life in patients with OSCC. The aim of this study was to identify the prognostic value of CDKN2A and miRNAs, involved in its regulation as markers of OSCC.
Methods
In the present study we have results of the examination and treatment of 70 patients with stage II–IV OSCC. miR-10b and -155 and mRNA of CDKN2A in tumor samples of patients with OSCC was analyzed by real-time reverse transcription polymerase chain reaction. Detection of p16INK4a was performed by simultaneous immunohistochemical assessment in tumor cells.
Results
We found a strong correlation of studied miRNAs expression with lymph node metastasis (r=0.56 for miR-10b and 0.59 for miR-155). Also, there is no differences in miR-10b and -155 between p16INK4a+ and p16INK4a- samples. p16INK4a status does not affect the association of both miRNAs with lymph node metastases.
Conclusions
The results indicate the relation between miR-10b and -155 and the presence of lymph node metastases of patients with OSCC and thus they can be used as prognostic markers of the disease.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
146P - The prognosis value of heat-shock proteins in esophagogastric cancer: A systematic review and meta-analysis
Presenter: Eric Nakamura
Session: Cocktail & Poster Display session
Resources:
Abstract
148P - Identification of potential predictive biomarkers for ovarian cancer chemotherapy response
Presenter: Alsina Nurgalieva
Session: Cocktail & Poster Display session
Resources:
Abstract
149P - Rare RAS mutations are associated with recurrence patterns and recurrence-free survival in colon cancer: First results from Morocco
Presenter: Fatima Agy
Session: Cocktail & Poster Display session
Resources:
Abstract
151P - Development of a predictive model for response to neoadjuvant chemoradiation therapy of rectal cancer using the immunologic profile
Presenter: Eun Shin
Session: Cocktail & Poster Display session
Resources:
Abstract
152P - Biomarkers of neoadjuvant chemoradiotherapy response in locally advanced rectal cancer
Presenter: Cibele Masotti
Session: Cocktail & Poster Display session
Resources:
Abstract
153P - BRAF variants and therapy outcomes in melanoma
Presenter: Eftychia Chatziioannou
Session: Cocktail & Poster Display session
Resources:
Abstract
154P - The impact of proton pump inhibitors in the prognosis of patients with non-metastatic nasopharyngeal carcinoma
Presenter: João Barbosa Martins
Session: Cocktail & Poster Display session
Resources:
Abstract
155P - Use of machine learning for the identification of molecular biomarkers to predict response to neoadjuvant chemotherapy in locally advanced breast cancer patients
Presenter: María Del Río Pisula
Session: Cocktail & Poster Display session
Resources:
Abstract
156P - Molecularly driven therapy recommended by a molecular tumor board: Accessible option or privilege for a minority of patients? A single-center experience from the Czech Republic
Presenter: Michal Eid
Session: Cocktail & Poster Display session
Resources:
Abstract
157P - PCM4EU academy: An educational program for precision oncology
Presenter: Loic Verlingue
Session: Cocktail & Poster Display session
Resources:
Abstract